Taiwan Liposome initiated at Janney Montgomery Scott

Taiwan Liposome initiated with a Buy at Janney Montgomery Scott. Janney Montgomery Scott analyst Esther Hong initiated Taiwan Liposome with a Buy rating and $13 fair value estimate, noting that the company has developed two proprietary lipid technology platforms and four clinical stage compounds across pain management, ophthalmology, and oncology. He estimates TLC599, the furthest along in development, has the potential for U.S. sales of $720M in 2028 and believes Taiwan Liposome will be a commercial stage company within a few years.
https://thefly.com/landingPageNews.php?id=2837827